Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares. Vertex’s suzetrigine, branded Journavx, was recently ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.